FDA Approves New Combivent Inhaler For Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim Pharmaceuticals Inc. Oct. 7 announced that the Food and Drug Administration has approved Combivent Respimat (ipratropium bromide and albuterol) inhalation spray, a new, propellant-free product.

The product uses a slow-moving mist to deliver the same active ingredients of Combivent inhalation aerosol in a metered dose inhaler (Combivent MDI), the company said. Combivent Respimat and Combivent MDI are indicated for patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have bronchospasm and who require a second bronchodilator, the company said. Combivent Respimat uses a new type of inhaler with a propellant-free delivery mechanism ...